



UNIVERSITAS NAHDLATUL ULAMA SURABAYA

LEMBAGA PENELITIAN DAN PENGABDIAN KEPADA MASYARAKAT

Kampus A Wonokromo : Jl. SMEA No.57 Tlp. 031-8291920, 8284508 Fax. 031-8298582 – Surabaya 60243

Kampus B RSIJemursari : Jl. Jemursari NO.51-57 Tlp. 031-8479070 Fax. 031-8433670 – Surabaya 60237

Website : unusa.ac.id Email: info@unusa.ac.id

SURAT KETERANGAN

Nomor: 854/UNUSA-LPPM/Adm-I/IV/2024

Lembaga Penelitian dan Pengabdian Kepada Masyarakat (LPPM) Universitas Nahdlatul Ulama Surabaya menerangkan telah selesai melakukan pemeriksaan duplikasi dengan membandingkan artikel-artikel lain menggunakan perangkat lunak **Turnitin** pada tanggal 12 Juni 2023.

Judul : *Self-Screening as an Effort to Prevent the Risk of Exposure to COVID-19 in Pregnant Women*

Penulis : Raden Khairiyatul Afiyah¹ *, Farida Umamah¹ , Ratna Yunita Sari¹ , Siti Nur Hasina¹ , Sulistyorini Sulistyorini¹ , Budi Prasetyo² , Supatmi Supatmi³

No. Pemeriksaan : 2024.04.29.371

Dengan Hasil sebagai Berikut:

Tingkat Kesamaan diseluruh artikel (*Similarity Index*) yaitu 15%

Demikian surat keterangan ini dibuat untuk digunakan sebagaimana mestinya

Surabaya, 29 April 2024

Ketua LPPM,

Achmad Syafiuddin, Ph.D.

NPP. 20071300

LPPM Universitas Nahdlatul Ulama Surabaya

Website : lppm.unusa.ac.id

Email : lppm@unusa.ac.id

Hotline : 0838.5706.3867

11._JIR_Self.pdf

by

Submission date: 12-Jun-2023 03:29PM (UTC+0700)

Submission ID: 2114351189

File name: 11._JIR_Self.pdf (493.37K)

Word count: 4544

Character count: 23569

more likely to die from COVID-19 with a prevalence of 1.5 deaths/1000 women. Meanwhile, women who are not pregnant have a mortality prevalence of 1.2/1000 women who are not pregnant [13].

Data from the Surabaya City Health Office, in 2021, show an increase in cases of pregnant women who are confirmed to be COVID-19 compared to cases in 2020 (Surabaya Health Office data in July 2020) at least 20 pregnant women who are positive for COVID-19 [1], [2].

The Centers for Disease Control and Prevention states, if infected with COVID-19, pregnant women will experience more severe conditions compared to non-pregnant women, because the number of confirmed cases of pregnant women with COVID-19 in a number of major cities in Indonesia has increased and the condition of pregnant women has increased. Already in severe condition, the present condition is worrying for all elements of society, including pregnant women. Moreover, that concern must be followed by anticipatory steps [14].

Efforts to reduce COVID-19 cases in pregnant women are an important intervention, in addition to several treatment and management programs that have been determined by the government, prevention efforts can be done independently by yourself by means of self-screening, with the aim of knowing how high the risk of pregnant women is exposed to COVID-19 [15].

Self-screening can be in the form of questions related to health protocol actions for pregnant women which include the following ways: (1) Must wear a mask, (2) diligently wash hands, (3) avoid crowds by keeping a distance, (4) reduce mobilization, (5) doing COVID-19 vaccination, (6) consumption of pregnancy vitamins, (7) eating a nutritious and balanced diet, (8) good stress management, (9) rest/sleep enough, and (10) light exercise. With this independent action, it is hoped that it can reduce cases and provide appropriate treatment early if pregnant women are confirmed positive for COVID [16].

Methods

This type of research uses experimental quantitative research using a randomized controlled trial research design. This research was conducted within 2 weeks in August–September 2021, sampling using consecutive sampling technique. The sample in this study was pregnant women in Surabaya who were included in the research criteria. The inclusion criteria in this study were pregnant women in Surabaya, not being sick, and willing to participate in the study for up to 2 weeks. The exclusion criteria in this study were respondents who were not willing to participate until the

end of this study. In this study, each respondent agreed by filling out a consent form. Participants in this study have the right to withdraw.

This study was divided into two groups, namely, the intervention group and the control group. The intervention group was given treatment in the form of self-screening for 2 weeks, while the control group did not receive any treatment. The intervention group with 39 respondents and the control group with 39 respondents. The procedure in this study is that the researcher obtains research permission first then the researcher visits pregnant women in Surabaya, precisely in the Southern part, pregnant women who agree to be involved in the study. Respondents signed an informed consent and participants had the right to withdraw. In this study, participants received two questionnaires in the form of demographic data (parity, occupation, husband's occupation, history of illness, and history of the COVID-19 vaccine) and a behavioral questionnaire to prevent the risk of being exposed to COVID-19 based on behavioral theory and had a reliability of 0.89 and a test the validity of the Cronbach alpha value obtained is 0.86. Data analysis used the Wilcoxon signed ranks test with a significance value of $p < 0.05$.

Results

Table 1 shows that the characteristics of the respondents in this study based on parity showed that almost half (23.1%) of the respondents were in the primiparous intervention group, while for the control group, the majority (25.6%) were primiparous respondents. Characteristics of respondents by occupation showed that almost all (34.3%) in the intervention group did not work while in the control group almost all (34.6%) worked. Characteristics of respondents according to the disease history showed almost entirely (28.2%) in the intervention group, there was no history of disease while in the control group

Table 1: Frequency distribution of respondents' characteristics in the intervention and control groups

Characteristics	Intervention Group (n = 39)		Control Group (n = 39)	
	f	%	f	%
Paritas Nullipara	6	7.7	2	2.6
Perimipara	16	23.1	20	25.6
Multipara	18	19.2	17	21.8
Job				
Work	20	19.6	27	34.6
Does not work	35	34.3	12	15.4
Disease history				
Disease	17	21.8	35	5.1
No Disease	22	28.2	4	44.9
COVID-19 vaccine history				
No vaccine	19	24.4	13	16.7
Vaccine	20	25.6	26	33.3
Husband's job				
WFO	33	42.3	11	14.1
WFH	6	7.7	28	35.9

WFO: Work from office, WFH: Work from home.

almost entirely (44.9%) had no history of disease. Characteristics of respondents according to the history of the COVID-19 vaccine showed almost entirely (33.3%) in the intervention group there was a history of the COVID-19 vaccine, while in the control group almost all (44.9%) had no history of the vaccine. Characteristics of respondents according to the husband's occupation showed almost entirely (42.3%) in the intervention group husbands worked from office (WFO) while in the control group almost all (35.9%) husbands worked from home (WFH).

Table 2 shows that the results of the normality test for behavioral variables **1** prevent the risk of being exposed to COVID-19 pre-test and post-test in the intervention group and control group **1** with the Kolmogorov–Smirnov test obtained $p > 0.05$ which means that the data distribution is normally distributed so that the analysis the data can be continued using the Wilcoxon signed ranks test statistic test.

Table 2: Test for normality of behavior to prevent the risk of being exposed to COVID-19 in the intervention group and control group (n = 39; n = 39)

Group	Behavior to prevent exposure to COVID-19	P
Intervention	Pre-test behavior to prevent exposure to COVID-19	0.596
	Post-test behavior to prevent exposure to COVID-19	0.000
Control	Pre-test behavior to prevent exposure to COVID-19	0.015
	Post-test behavior to prevent exposure to COVID-19	0.005

Table 3 shows that the average behavior to prevent the risk of being exposed to COVID-19 in the intervention group was 1.92 (the behavior to prevent the risk of being exposed to COVID-19 was **2** sufficient) and 1.85 in the control group (the behavior to prevent the risk of being exposed to COVID-19 was sufficient) with $p = 0.596$, which means that there is no difference in the average behavior to **1** prevent the risk of being exposed to COVID-19 enough in the intervention group and the control group before the intervention.

Table 3: Behavior to prevent the risk of being exposed to COVID-19 in the intervention group and the control group before being given the intervention (n = 39; n = 39)

Group	Mean	SD	Min	Max	SE	p-value
Intervention	1.92	0.700	1	1	0.113	0.596
Control	1.85	0.812	1	1	0.130	

Table 4 shows that the average behavior to prevent the risk of being exposed to COVID-19 in the intervention group is 2.46 (the behavior to prevent the risk of being exposed to COVID-19 is good) and 2.05 in the control group (the behavior to prevent the risk of being exposed to COVID-19 is good) with $p = 0.000$ means that there is an average difference in behavior **1** to prevent the risk of being exposed to COVID-19 in the intervention group and the control group after being given the intervention.

Table 4: Behavior to prevent the risk of being exposed to COVID-19 in the intervention group and the control group after being given the intervention (n = 39; n = 39)

Group	Mean	SD	Min	Max	SE	p-value
Intervention	2.46	0.643	1	1	0.103	0.000
Control	2.05	0.823	13	3	0.122	

Based on Table 5, the results of the Wilcoxon signed ranks test statistic obtained $p = 0.000$ in the intervention group and $p = 0.005$ in the control group, $p < 0.05$, it can be concluded that there is a significant change in behavior to prevent the risk of being exposed to COVID-19 before **1** and after being given a self-screening intervention **1** in the intervention group and the control group.

Table 5: The level of anxiety (pre- and post-test) in the intervention group and control group (n = 39; n = 39)

Group	Mean	SD	Count statistic	p-value
Intervention	Pre	1.92	14.1	0.000
	Post	2.46	0.643	
Control	Pre	1.85	-2.7	0.005
	Post	2.05	0.823	

Discussion

3 Pregnant women in the era **3** of the COVID-19 pandemic were listed as one of the vulnerable groups at risk of being infected with COVID-19 because during pregnancy there were changes in gestational physiology and immunological changes in the body's system [1]. Experts are still studying the effect of COVID-19 or coronavirus infection on pregnant women [2]. However, changes in the immune system that occur during pregnancy can make pregnant women more susceptible to coronavirus infection and more at risk of experiencing severe and fatal disease symptoms [3].

Efforts to reduce COVID-19 cases in pregnant women are an important intervention, in addition to several treatment and management programs that have been determined by the government, prevention efforts can be done independently by yourself by means of self-screening, with the aim of knowing how high the risk of pregnant women is exposed to COVID-19 [15].

Self-screening can be in the form of questions related to health protocol actions for pregnant women which include the following ways: (1) Must wear a mask, (2) diligently wash hands, (3) avoid crowds by keeping a distance, (4) reduce mobilization, (5) doing COVID-19 vaccination, (6) consumption of pregnancy vitamins, (7) eating a nutritious and balanced diet, (8) good stress management, (9) rest/sleep enough, and (10) light exercise. With this independent action, it is hoped that it can reduce cases and provide appropriate treatment early if pregnant women are confirmed positive for COVID [16].

The results of the study **2** are the intervention showed that the average behavior to prevent the risk of being exposed to COVID-19 in the intervention group was 1.92 (the behavior to prevent the risk of being exposed to COVID-19 was sufficient) and 1.85 in the control group (the behavior to prevent the risk of being

exposed to COVID-19 was sufficient). With $p = 0.596$, it means that there is no difference in the average behavior of preventing the risk of being exposed to COVID-19 enough in the intervention group and the control group before the intervention. After being given the intervention, it showed that the average behavior to prevent the risk of being exposed to COVID-19 in the intervention group was 2.46 (the behavior to prevent the risk of being exposed to COVID-19 was good) and 2.05 in the control group (the behavior to prevent the risk of being exposed to COVID-19 was good) with $p = 0.000$ which means that there is a difference in the average behavior of preventing the risk of being exposed to COVID-19 in the intervention group and the control group after being given the intervention.

The United campaign against COVID-19 is based on a risk approach to the pandemic situation. The communication approach used is different from health communication in general. For a pandemic situation like COVID-19, a risk communication approach is used which refers to increasing public knowledge including groups of pregnant women who are at high risk and on the potential risks and threats of health problems so that they are able to decide on steps and actions that can protect themselves from these problems [17]. The World Health Organization defines risk communication as the exchange of information and views on risks and risk-related factors among groups at high risk of contracting COVID-19 [18].

In a pandemic situation like this, many parties have made various communication efforts simultaneously and at the same time. On the one hand, this situation provides an advantage for the public to quickly get the latest information. However, on the other hand, it has a weakness, namely, messages that are issued too much are random (impulsive) and always changing will create noise that interferes with receiving the message and ultimately prevents people from understanding it and changing their behavior [19]. Therefore, it is important for communicators to pay attention and prioritize key behavior change goals that are considered essential to effectively and efficiently reduce COVID-19 cases [20].

Self-screening is one way to convince pregnant women that the COVID-19 condition can be controlled if they are willing to take action and respond in accordance with the suggestions/messages conveyed and the message is effective in reducing transmission, easy to understand, and can be done [21]. Therefore, it is hoped that the ability of pregnant women to assess themselves including the risk or not being exposed to COVID-19 as a way to reduce the high mortality rate in pregnant women during the COVID-19 pandemic [22]. Behavior to prevent exposure to COVID-19 in pregnant women will appear if they feel a threatening condition and consider themselves a risk group [23]. Behavior to prevent exposure to COVID-19 in pregnant women is influenced by several factors, namely, self and

environmental factors including husbands, work, and the COVID-19 vaccine [24]. In this study, the results obtained in the intervention group. Most of them did not work, in the control group most worked. In the intervention and control groups, most had no history of disease/comorbidities. In the intervention group, most of them had done the COVID-19 vaccine and in the control group, most of them did not get the COVID-19 vaccine. The most of the parity group aged 15–25 years were still classified as teenagers. In addition, in this study, it was found that most of them were women and did not work. In the intervention group, the most of the husbands worked WFO and in the control group most were WFH. Some of the factors above are a threat to the ease with which pregnant women are exposed to COVID-19, therefore, education and supervision must be provided, especially for husbands and other members and the most important thing is the administration of the COVID-19 vaccine [25], [26], [27].

Conclusion

This study proves that self-screening can foster behavior to prevent the risk of being exposed to COVID-19 in pregnant women. The role of the maternity nurse in this problem is to provide education about the importance of health protocol behavior to prevent exposure to COVID-19 in pregnant women. Suggestions for the next research are to increase the number of respondents, variables, and expand the research location.

References

1. Singgih S, Sukartini T, Afiyah RK. Response of patients confirmed COVID-19 after undergoing treatment in the isolation room. *J Keperawatan*. 2021;13(3):619-28.
2. Afiyah RK, Kamariyah N, Wijayanti L, Yhusnain JR. Fulfillment of exercise needs among pregnant women during the COVID-19 Pandemic. *Nurse Holistic Care*. 2021;1(2):89-97.
3. Berghella V. Coronavirus Disease 2019 (COVID-19): Pregnancy Issues. Massachusetts, United States: UpToDate Internet; 2020.
4. Belingheri M, Paladino ME, Riva MA. Risk exposure to Coronavirus disease 2019 in pregnant healthcare workers. *J Occup Environ Med*. 2020;62(7):e370. <https://doi.org/10.1097/JOM.0000000000001881>
PMid:32730041
5. Omer S, Ali S. Preventive measures and management of COVID-19 in pregnancy. *Drugs Ther Perspect*. 2020;36(6):246-9. <https://doi.org/10.1007/s40267-020-00725-x>
PMid:32292265
6. Yang H, Wang C, Poon LC. Novel coronavirus infection and pregnancy. *Ultrasound Obstet Gynecol*. 2020;55(4):435-7.

- <https://doi.org/10.1002/uog.22006>
PMid:32134165
7. Ahorsu DK, Imani V, Lin CY, Timpka T, Broström A, Updegraff JA, *et al.* Associations between fear of COVID-19, mental health, and preventive behaviours across pregnant women and husbands: An actor-partner interdependence modelling. *Int J Ment Health Addict.* 2020; 11:1-5. <https://doi.org/10.1007/s11469-020-00340-x>
PMid:32837427
 8. London V, McLaren R Jr., Atallah F, Cepeda C, McCalla S, Fisher N, *et al.* The relationship between status at presentation and outcomes among pregnant women with COVID-19. *Am J Perinatol.* 2020;37(10):991-4. <https://doi.org/10.1055/s-0040-1712164>
PMid:32428964
 9. Nwafor JI, Aniuoku JK, Anozie BO, Ikeotuonye AC. Knowledge and Practice of Preventive Measures Against COVID-19 Infection among Pregnant Women in a Low-Resource African Setting, *MedRxiv*; 2020.
 10. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, *et al.* Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet.* 2020;395(10226):809-15. [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3)
PMid:32151335
 11. Fesler MC, Stricker RB. Pre-exposure prophylaxis for COVID-19 in pregnant women. *Int J Gen Med.* 2021;14:279-84. <https://doi.org/10.2147/IJGM.S295627>
PMid:33542646
 12. Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: What obstetricians need to know. *Obstet Gynecol.* 2021;137(3):408-14. <https://doi.org/10.1097/AOG.0000000000004290>
PMid:33370015
 13. Chawla D, Chirila D, Dalwai S, Deorari AK, Ganatra A, Gandhi A, *et al.* Perinatal-neonatal management of COVID-19 infection-guidelines of the Federation of Obstetric and Gynaecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP). *Indian Pediatr.* 2020;57(6):536-48. <https://doi.org/10.1007/s13312-020-1852-4>
PMid:32238615
 14. Vardhelli V, Pandita A, Pillai A, Badatya SK. Perinatal COVID-19: Review of current evidence and practical approach towards prevention and management. *Eur J Pediatr.* 2021;180(4):1009-31. <https://doi.org/10.1007/s00431-020-03866-3>
PMid:33184730
 15. Durankuş F, Aksu E. Effects of the COVID-19 pandemic on anxiety and depressive symptoms in pregnant women: A preliminary study. *J Matern Fetal Neonatal Med.* 2022;35(2):205-11. <https://doi.org/10.1080/14767058.2020.1763946>
PMid:32419558
 16. Craig AM, Hughes BL, Swamy GK. Coronavirus disease 2019 vaccines in pregnancy. *Am J Obstet Gynecol MFM.* 2021;3(2):100295. <https://doi.org/10.1016/j.ajogmf.2020.100295>
PMid:33516986
 17. Dashraath P, Wong JL, Lim MX, Lim LM, Li S, *et al.* Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol.* 2020;222(6):521-31. <https://doi.org/10.1016/j.ajog.2020.03.021>
PMid:32217113
 18. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, *et al.* Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. *JAMA Pediatr.* 2021;175(8):817-26. <https://doi.org/10.1001/jamapediatrics.2021.1050>
PMid:33885740
 19. Woodworth KR, Olsen EO, Neelam V, Lewis EL, Galang RR, Oduyebo T, *et al.* Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy-SET-NET, 16 jurisdictions, March 29-October 14, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(44):1635-40. <https://doi.org/10.15585/mmwr.mm6944e2>
PMid:33151917
 20. Wu D, Fang D, Wang R, Deng D, Liao S. Management of pregnancy during the COVID-19 pandemic. *Glob Chall.* 2021;5(2):2000052. <https://doi.org/10.1002/gch2.202000052>
PMid:33173591
 21. Rasmussen SA, Smulian JC, Lednický JA, Wen TS, Jamieson DJ. Coronavirus disease 2019 (COVID-19) and pregnancy: What obstetricians need to know. *Am J Obstet Gynecol.* 2020;222(5):415-26. <https://doi.org/10.1016/j.ajog.2020.02.017>
PMid:32105680
 22. Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H, *et al.* Global interim guidance on Coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. *Int J Gynecol Obstet.* 2020;149(3):273-86. <https://doi.org/10.1002/ijgo.13156>
PMid:32248521
 23. Boelig RC, Manuck T, Oliver EA, di Mascio D, Saccone G, Bellussi F, *et al.* Labor and delivery guidance for COVID-19. *Am J Obstet Gynecol MFM.* 2020;2(2):100110. <https://doi.org/10.1016/j.ajogmf.2020.100110>
PMid:32518901
 24. Poon LC, Yang H, Lee JC, Copel JA, Leung TY, Zhang Y, *et al.* ISUOG Interim Guidance on 2019 novel Coronavirus infection during pregnancy and puerperium: Information for healthcare professionals. *Ultrasound Obstet Gynecol.* 2020;55(5):700-8. <https://doi.org/10.1002/uog.22013>
PMid:3216034
 25. Asadi L, Tabatabaei RS, Safinejad H, Mohammadi M. New Corona virus (COVID-19) management in pregnancy and childbirth. *Arch Clin Infect Dis.* 2020;15:e102938. <https://doi.org/10.5812/archcid.102938>
 26. Ryan GA, Purandare NC, McAuliffe FM, Hod M, Purandare CN. Clinical update on COVID-19 in pregnancy: A review article. *J Obstet Gynaecol Res.* 2020;46(8):1235-45.
 27. Farrell R, Michie M, Pope R. Pregnant women in trials of COVID-19: A critical time to consider ethical frameworks of inclusion in clinical trials. *Ethics Hum Res.* 2020;42(4):17-23. <https://doi.org/10.1002/eahr.500060>
PMid:32562594

11._JIR_Self.pdf

ORIGINALITY REPORT

15%	%	%	15%
SIMILARITY INDEX	INTERNET SOURCES	PUBLICATIONS	STUDENT PAPERS

PRIMARY SOURCES

1	Submitted to Udayana University Student Paper	8%
2	Submitted to I-Shou International School Student Paper	3%
3	Submitted to Universitas Nahdlatul Ulama Surabaya Student Paper	3%
4	Submitted to The College of New Jersey Student Paper	2%

Exclude quotes On

Exclude matches < 2%

Exclude bibliography On